CoChat

Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective Receptor Modulators?

Open access
Vinkers, Christiaan H., Olivier, Berend · 2012 · Advances in Pharmacological Sciences

The DOI matches its Crossref record; 165 of the 166 references it cites were found in a registry or an index; 13 of the 168 sources its claims cite were checked for support.

Abstract

Despite decades of basic and clinical research, our understanding of how benzodiazepines tend to lose their efficacy over time (tolerance) is at least incomplete. In appears that tolerance develops relatively quickly for the sedative and anticonvulsant actions of benzodiazepines, whereas tolerance to anxiolytic and amnesic effects probably does not develop at all. In light of this evidence, we review the current evidence for the neuroadaptive mechanisms underlying benzodiazepine tolerance, including changes of (i) the receptor (subunit expression and receptor coupling), (ii) intracellular changes stemming from transcriptional and neurotrophic factors, (iii) ionotropic glutamate receptors, (iv) other neurotransmitters (serotonin, dopamine, and acetylcholine systems), and (v) the neurosteroid system. From the large variance in the studies, it appears that either different (simultaneous) tolerance mechanisms occur depending on the benzodiazepine effect, or that the tolerance-inducing mechanism depends on the activated receptor subtypes. Importantly, there is no convincing evidence that tolerance occurs with α subunit subtype-selective compounds acting at the benzodiazepine site.

Overview

CoChat Summary

TL;DR

This review synthesizes evidence on neuroadaptive mechanisms of benzodiazepine tolerance, concluding that tolerance develops relatively quickly for sedative/hypnotic and anticonvulsant effects but probably not for anxiolytic and amnesic effects. It finds no convincing evidence that α subunit subtype-selective compounds acting at the benzodiazepine site produce tolerance comparable to classical benzodiazepines.

Key findings

  • Tolerance is effect-specific: it develops rapidly for sedative/hypnotic and anticonvulsant actions, whereas tolerance to anxiolytic and amnesic effects most probably does not develop at all. Anticonvulsant tolerance develops during the first several months in 30–50% of epilepsy patients treated with clobazam or clonazepam.
  • Proposed mechanisms include GABA_A receptor uncoupling, altered subunit expression, ionotropic glutamate receptor changes, transcriptional/neurotrophic factors, serotonin/dopamine/acetylcholine systems, and neurosteroids; none sufficiently explains tolerance, and the literature is heterogeneous. α5 subunits comprise 15–20% of diazepam-sensitive GABA_A receptors, and α5 together with α1 subunits has been implicated in tolerance to diazepam’s sedative action.
  • Subtype-selective α2/α3 compounds show little tolerance in reviewed studies: no tolerance to acute hypothermic, anxiolytic, or sedative effects of diazepam in mice treated for 28 days with TPA023 (unpublished data), no analgesic tolerance after 9-day L838,417 in rats, and no sedative/anticonvulsant tolerance with chronic zolpidem but not midazolam in mice and rats. TPA023 has 0% α1 intrinsic activity versus 23% for TPA123; TPA123 led to benzodiazepine-like reinforcement and withdrawal, whereas TPA023 did not.
  • Clinical anxiolytic tolerance was not observed in a double-blind study of 180 chronically anxious outpatients given diazepam 15–40 mg/day for 6–22 weeks, nor after 8 weeks of alprazolam in panic disorder with continued efficacy.

Methods

  • Narrative review of basic and clinical literature; no primary experiments or systematic search/meta-analysis are described.
  • It reviews evidence on GABA_A receptor subunit expression and coupling, intracellular/transcriptional and neurotrophic factors, ionotropic glutamate receptors, serotonin/dopamine/acetylcholine systems, neurosteroids, and subtype-selective GABA_A receptor modulators.
  • Evidence includes preclinical rodent and nonhuman primate studies and clinical studies in insomnia, epilepsy, panic disorder, generalized anxiety disorder, social phobia, and healthy volunteers.

Limitations

  • The authors state that understanding of tolerance remains incomplete; studies show large variance due to different methodologies, species, treatment regimens, and benzodiazepines; classical benzodiazepines are treated as a homogeneous class, which may complicate interpretation; molecular results are often not combined with behavioral tests; clinical in vivo binding or postmortem GABA_A receptor expression studies are lacking; no studies directly investigate GABA_A receptor subunit composition after chronic exposure; preclinical tolerance is often not directly related to dose, dosing interval, plasma levels, or half-life; and many studies have relatively short exposure durations.
  • Evident from the text: this is a narrative review without a described systematic search or formal quality appraisal, and some key claims about subtype-selective compounds rely on unpublished data from the authors’ laboratory.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1155/2012/416864

Cites

165 of 165 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Representation of the GABAA receptor structure. The inhibitory GABAA receptor consists of five subunits that together form a ligand-gated chloride (Cl−) channel (a). When GABA binds (between the α and the β subunit of the GABAA receptor), chloride ions flow into the neuron, resulting in a hyperpolarization of the cell membrane (a). Classical nonselective benzodiazepines allosterically enhance the inhibitory actions of GABA by binding between the α 1, α 2, α 3, or α 5 subunit and the γ subunit (b). Although the GABAA receptor displays a large molecular heterogeneity depending on the subunit composition, the most common subtype is a pentamer with 2α, 2β, and 1γ subunit.
Figure 1 Representation of the GABAA receptor structure. The inhibitory GABAA receptor consists of five subunits that together form a ligand-gated chloride (Cl−) channel (a). When GABA binds (between the α and the β subunit of the GABAA receptor), chloride ions flow into the neuron, resulting in a hyperpolarization of the cell membrane (a). Classical nonselective benzodiazepines allosterically enhance the inhibitory actions of GABA by binding between the α 1, α 2, α 3, or α 5 subunit and the γ subunit (b). Although the GABAA receptor displays a large molecular heterogeneity depending on the subunit composition, the most common subtype is a pentamer with 2α, 2β, and 1γ subunit.CC BY · PubMed Central
Figure 2 GABAA receptor trafficking and associated proteins. GABAA receptors are assembled from individual subunits in the endoplasmatic reticulum (ER) where the chaperones BiP and Calnexin assist in quality control. Unassembled GABAA receptor subunits that are to be targeted for ER-associated degradation are ubiquitinated and degraded in the proteasome. The ubiquitin-like protein PLIC can interact with GABAA receptors thereby inhibiting their targeting for proteasomal degradation. Assembled pentameric GABAA receptors exit the ER and bind the guanidine exchange factor brefeldin-A-inhibited GDP/GTP exchange factor 2 (BIG2) in the Golgi. Here they also interact with the palmitoylase transferase GODZ and Gamma-aminobutyric acid receptor-associated protein (GABARAP). GABARAP interacts with the NEM sensitive fusion (NSF) protein, as does the GABAA receptor β subunit, and this association may facilitate transport of the receptor complexes to the cell surface. GABAA receptors are inserted at extrasynaptic sites and can diffuse along the plasma membrane in and out of synaptic domains. At synapses they are stabilized by an interaction with the scaffolding protein Gephyrin. The interaction of the GABAA receptor intracellular loops with the μ2 subunit of the adaptin complex AP2 is important for GABAA receptor internalization. GABAA receptors are delivered by a clathrin-mediated pathway to early endosomes where they can be targeted for degradation in the lysosome or for recycling upon binding of Huntington-associated protein (HAP1). Reprinted by permission from Elsevier, reprinted from [101].
Figure 2 GABAA receptor trafficking and associated proteins. GABAA receptors are assembled from individual subunits in the endoplasmatic reticulum (ER) where the chaperones BiP and Calnexin assist in quality control. Unassembled GABAA receptor subunits that are to be targeted for ER-associated degradation are ubiquitinated and degraded in the proteasome. The ubiquitin-like protein PLIC can interact with GABAA receptors thereby inhibiting their targeting for proteasomal degradation. Assembled pentameric GABAA receptors exit the ER and bind the guanidine exchange factor brefeldin-A-inhibited GDP/GTP exchange factor 2 (BIG2) in the Golgi. Here they also interact with the palmitoylase transferase GODZ and Gamma-aminobutyric acid receptor-associated protein (GABARAP). GABARAP interacts with the NEM sensitive fusion (NSF) protein, as does the GABAA receptor β subunit, and this association may facilitate transport of the receptor complexes to the cell surface. GABAA receptors are inserted at extrasynaptic sites and can diffuse along the plasma membrane in and out of synaptic domains. At synapses they are stabilized by an interaction with the scaffolding protein Gephyrin. The interaction of the GABAA receptor intracellular loops with the μ2 subunit of the adaptin complex AP2 is important for GABAA receptor internalization. GABAA receptors are delivered by a clathrin-mediated pathway to early endosomes where they can be targeted for degradation in the lysosome or for recycling upon binding of Huntington-associated protein (HAP1). Reprinted by permission from Elsevier, reprinted from [101].CC BY · PubMed Central
Figure 3 Functional crosstalk between G-protein coupled receptors (GPCRs) (which are present in the serotonin, dopamine, acetylcholine system) and GABAA receptors is facilitated through multiple protein kinases and scaffold proteins. GABAA receptor β and γ2 subunits are phosphorylated (P) by PKA and PKC upon the activation of individual GPCRs for dopamine and serotonin. PKA phosphorylation of GABAA receptor β1 and β3 subunits is dependent upon AKAP150/79, which directly interacts with these receptor subunits. AKAP150/79 also binds inactive PKA composed of regulatory (R) and catalytic (C) subunits. In addition, PKC phosphorylates the receptor β1–3 and γ2 subunits. Upon the activation of the appropriate GPCR, PKC-mediated phosphorylation is facilitated by the direct (but independent) interaction of the receptor for activated C kinase (RACK-1) and the β isoform of PKC with the GABAA receptor β1–3 subunits. RACK-1 facilitates functional regulation of GABAA receptors by controlling the activity of PKC associated with these proteins. The GABAA receptor γ2 subunit is also phosphorylated by Src, and this kinase is capable of binding to receptor β and γ2 subunits. Finally, the functional effects of phosphorylation are diverse and range from inhibitions to enhancements of GABAA receptor activity, dependent upon the receptor subunit composition. Reprinted by permission from Elsevier, reprinted from [95].
Figure 3 Functional crosstalk between G-protein coupled receptors (GPCRs) (which are present in the serotonin, dopamine, acetylcholine system) and GABAA receptors is facilitated through multiple protein kinases and scaffold proteins. GABAA receptor β and γ2 subunits are phosphorylated (P) by PKA and PKC upon the activation of individual GPCRs for dopamine and serotonin. PKA phosphorylation of GABAA receptor β1 and β3 subunits is dependent upon AKAP150/79, which directly interacts with these receptor subunits. AKAP150/79 also binds inactive PKA composed of regulatory (R) and catalytic (C) subunits. In addition, PKC phosphorylates the receptor β1–3 and γ2 subunits. Upon the activation of the appropriate GPCR, PKC-mediated phosphorylation is facilitated by the direct (but independent) interaction of the receptor for activated C kinase (RACK-1) and the β isoform of PKC with the GABAA receptor β1–3 subunits. RACK-1 facilitates functional regulation of GABAA receptors by controlling the activity of PKC associated with these proteins. The GABAA receptor γ2 subunit is also phosphorylated by Src, and this kinase is capable of binding to receptor β and γ2 subunits. Finally, the functional effects of phosphorylation are diverse and range from inhibitions to enhancements of GABAA receptor activity, dependent upon the receptor subunit composition. Reprinted by permission from Elsevier, reprinted from [95].CC BY · PubMed Central

Verification

Claims the paper makes

7 Valid · 4 Not valid · 97 Not checked · 61 Own results and interpretations

96 more claims · 1 with their cited sources checked

Create a free account to see all 169 claims and to verify the 155 references still open.

See all claims — free account
  • It may state two separate claims as one. 53
  • Probably not a substantial claim. 23

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 165 references

Research works printed but not linked: 1

  1. Ko D Rho JM DeGiorgio CM Sato S Engel JJ Pedley TA Benzodiazpines Epilepsy: A Comprehensive Textbook 1997 Philadelphia, Pa, USA Lippincott-Raven 1475 1489

Cited by

See all 225

Metadata

Authors
Vinkers, C. H., & Olivier, B.
Affiliations
Utrecht University (NL)
Corresponding author
Vinkers, Christiaan H.
Venue
Advances in Pharmacological Sciences
Publisher
Wiley
Published
2012
Volume
2012
Pages
1-19
ISSN
  • 1687-6334 (ISSN-L)
  • 1687-6342
OpenAlex
W2041124713
Cited by
195
References
166
Citations by year
2026: 10 · 2025: 12 · 2024: 7 · 2023: 10 · 2022: 17 · 2021: 18 · 2020: 24 · 2019: 16 · 2018: 18 · 2017: 9 · 2016: 16 · 2015: 15 · 2014: 11 · 2013: 8 · 2012: 4
FWCI
5.01
Type
journal article
Language
en
Open access
Locations
  • Advances in Pharmacological Sciences (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
  • Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
Keywords
benzodiazepine tolerance, GABAA receptor, receptor subunit expression, receptor coupling, neural adaptation, neurotrophic factors, transcriptional regulation, ionotropic glutamate receptors, serotonin, dopamine, acetylcholine, neurosteroids, anxiolytic effects

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.